Search results
Author(s):
Lars H Lund
Added:
1 year ago
Prof Lars Lund (Karolinska Institute, SE) outlines the findings of the ALLEVIATE-HF-1 and ALLEVIATE-HF-2 studies at 6 months. Presented at Heart Failure 22, this study aimed to evaluate a no-implant shunt in patients with chronic heart failure.
Discussion Points:
1. Aims of This Study
2. No-Implant Interatrial Shunt
3. Inclusion and Exclusion Criteria, Patient Cohort and Study Design
4. Key…
View more
Author(s):
Stephen J Greene
Added:
10 months ago
ESC-HFA 23 — Dr Stephen Greene (Duke University School of Medicine, US) outlines the findings from the QoL study of the TRANSFORM-HF Trial (NCT03296813).
The TRANSFORM-HF trial is a randomized trial which compared torsemide to furosemide as a treatment for patients with heart failure. Around 2859 patients with heart failure were enrolled in the trial, whose clinical outcomes were measured across…
View more
Author(s):
Rajalakshmi Santhanakrishnan
Added:
3 years ago
Heart failure (HF) is a major health problem and about 6 million adults are affected in the US alone, at a cost of approximately $20 billion per year.1 Despite the availability of new treatment strategies, the incidence, number of hospitalizations and mortality associated with HF remains a big health burden.1 In addition to increasing age, the factors that contribute to poor prognosis for people…
View more
Treating Atherogenic Dyslipidemia in Patients with Type 2 Diabetes—The Case for Using Fenofibrate
Author(s):
Sergio Fazio
Added:
3 years ago
Article
Author(s):
Shanmugam Uthamalingam
,
James L Januzzi
Added:
3 years ago
Several cardiac biomarkers may aid in the diagnostic and prognostic evaluation of acute and chronic heart failure. In this article we discuss more novel and emerging applications of such established cardiac biomarkers in heart failure and review emerging data for several other promising markers.
Novel Applications of Established Cardiac Biomarkers—Natriuretic Peptides
B-type natriuretic peptide…
View more
Author(s):
Uwe Zeymer
Added:
4 months ago
AHA 23 - We are joined on-site by Prof Uwe Zeymer (Klinikum Ludwigshafen, Ludwigshafen, DE) to discuss the findings from a sub-analysis of the ECLS-SHOCK trial.This sub-analysis investigates the impact of cardiac arrest before randomisation on the efficacy of ECLS in patients with infarct-related cardiogenic shock. Investigators enrolled 420 patients with acute MI and cardiogenic shock across 41…
View more
The Digital Ballistocardiograph
Author(s):
Geoffrey Houlton
Added:
3 years ago
Article
Homocysteine-lowering Treatment in Reduction of Stroke and Coronary Vascular Risk - Do Not Give Up
Author(s):
Wolfgang Herrmann
,
Rima Obeid
Added:
3 years ago
Article
Author(s):
Marc P Bonaca
Added:
1 year ago
AHA 22 - Dr Marc Bonaca (University of Colorado School of Medicine, Aurora, Colorado, US) joins us to discuss the findings of the BT001 Pivotal Trial, originally presented at AHA 2022.
BT001 Pivotal aimed to study the use of a mobile app that delivered nutritional cognitive behavioural therapy (nCBT) for the treatment of type II diabetes. The application targets behaviours which are associated…
View more
Added:
1 year ago
HFSA 22 - In this interview, Dr Juuso Blomster (Precordior Ltd, Turku, FI) joins us to share the results of the REFLECS Trial (NCT04378179), originally presented at HFSA 2022.
This trial aimed to evaluate the Precordior CardioSignal app's efficacy in measuring patients cardiac motion and function in comparison to echocardiography. Over 200 patients were recruited to this observational study.
…
View more